LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 10 von insgesamt 143

Suchoptionen

  1. Buch: Congenital Bleeding Disorders

    Dorgalaleh, Akbar

    Diagnosis and Management

    2023  

    Verfasserangabe Akbar Dorgalaleh is a hematologist and scientific researcher in the field of thrombosis and hemostasis. He has (co-)authored over 120 papers, and is a member of the editorial boards of several international journals. Dr. Dorgalaleh is also a current or past member of several International scientific societies or working parties, including International Society on Thrombosis and Hemostasis (ISTH) Scientific Standardization Committees (SSCs) on Subcommittee on Factor XIII and Fibrinogen and International Council for Standardization in Haematology (ICSH)
    Schlagwörter CommonBleedingDisorders ; VonWillebrandDisorders ; HemophiliaA ; HemophiliaB ; RareBleedingDisorders ; GlanzmannThrombasthenia ; Bernard-SoulierSyndrome ; GrayPlateletSyndrome ; QuebecPlateletDisorder ; CombinedCoagulationFactorDefiencies ; CongenitalFactorIdisorders ; CongenitalFactorIIdeficiency ; CongenitalFactorVdeficiency ; CongenitalFactorVIIdeficiency ; CongenitalFactorXdeficiency ; Common Bleeding Disorders ; Von Willebrand Disorders ; Hemophilia A ; Hemophilia B ; Rare Bleeding Disorders ; Glanzmann Thrombasthenia ; Bernard-Soulier Syndrome ; Gray Platelet Syndrome ; Quebec Platelet Disorder ; Combined Coagulation Factor Defiencies ; Congenital Factor I disorders ; Congenital Factor II deficiency ; Congenital Factor V deficiency ; Congenital Factor VII deficiency ; Congenital Factor X deficiency
    Sprache Englisch
    Umfang 480 p.
    Ausgabenhinweis 2
    Verlag Springer International Publishing
    Dokumenttyp Buch
    Anmerkung PDA Manuell_24
    Format 160 x 241 x 30
    ISBN 9783031431555 ; 3031431553
    Datenquelle PDA

    Kategorien

  2. Buch ; Online ; E-Book: Congenital bleeding disorders

    Dorgalaleh, Akbar

    diagnosis and management

    2018  

    Verfasserangabe Akbar Dorgalaleh editor
    Schlagwörter Medicine ; Hematology ; Pediatrics
    Thema/Rubrik (Code) 616.15
    Sprache Englisch
    Umfang 1 Online-Ressource (XIV, 396 Seiten), Illustrationen, Diagramme
    Verlag Springer
    Erscheinungsort Cham
    Erscheinungsland Schweiz
    Dokumenttyp Buch ; Online ; E-Book
    Bemerkung Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
    HBZ-ID HT019791899
    ISBN 978-3-319-76723-9 ; 9783319767222 ; 3-319-76723-2 ; 3319767224
    DOI 10.1007/978-3-319-76723-9
    Datenquelle ZB MED Katalog Medizin, Gesundheit, Ernährung, Umwelt, Agrar

    Kategorien

  3. Artikel ; Online: Novel Insights into Heterozygous Factor XIII Deficiency.

    Dorgalaleh, Akbar

    Seminars in thrombosis and hemostasis

    2023  Band 50, Heft 2, Seite(n) 200–212

    Abstract: The prevalence and clinical significance of heterozygous factor XIII (FXIII) deficiency has long been debated, with controversial reports emerging since 1988. In the absence of large epidemiologic studies, but based on a few studies, a prevalence of 1 ... ...

    Abstract The prevalence and clinical significance of heterozygous factor XIII (FXIII) deficiency has long been debated, with controversial reports emerging since 1988. In the absence of large epidemiologic studies, but based on a few studies, a prevalence of 1 per 1,000 to 5,000 is estimated. In southeastern Iran, a hotspot area for the disorder, a study of more than 3,500 individuals found an incidence of 3.5%. Between 1988 and 2023, a total of 308 individuals were found with heterozygous FXIII deficiency, of which molecular, laboratory, and clinical presentations were available for 207 individuals. A total of 49 variants were found in the
    Mesh-Begriff(e) Pregnancy ; Female ; Humans ; Heterozygote ; Factor XIII/genetics ; Factor XIII/metabolism ; Factor XIII Deficiency/genetics ; Factor XIII Deficiency/complications ; Mutation ; Postpartum Hemorrhage
    Chemische Substanzen Factor XIII (9013-56-3)
    Sprache Englisch
    Erscheinungsdatum 2023-03-20
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 196901-8
    ISSN 1098-9064 ; 0094-6176
    ISSN (online) 1098-9064
    ISSN 0094-6176
    DOI 10.1055/s-0043-1764471
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel ; Online: The History of Factor XIII Deficiency.

    Dorgalaleh, Akbar

    Seminars in thrombosis and hemostasis

    2023  Band 50, Heft 1, Seite(n) 34–42

    Abstract: Despite the early discovery of factor XIII (FXIII) in 1944, the diagnosis of FXIII deficiency was not made until 1960, after all the other coagulation factor deficiencies, most likely due to the normality of routine coagulation testing in FXIII ... ...

    Abstract Despite the early discovery of factor XIII (FXIII) in 1944, the diagnosis of FXIII deficiency was not made until 1960, after all the other coagulation factor deficiencies, most likely due to the normality of routine coagulation testing in FXIII deficiency. Although the first case was detected by the clot solubility test and this test has long since been used to detect FXIII deficiency, the test is no longer recommended by experts. Over the past 60 years, knowledge about FXIII deficiency has expanded considerably, between 1992, when the first variant was identified, and 2022, 197 mutations have been reported. Almost all missense mutations have a similar effect on FXIII, leading to instability and faster degradation of mutant FXIII protein. Therapeutic options have evolved from historical fresh frozen plasma (FFP), old plasma, whole blood, and cryoprecipitate, to plasma-derived and recombinant FXIII concentrates, respectively available since 1993 and 2012. These concentrate products were respectively approved by the Food and Drug Administration in 2011 and 2013. This historical review covers various aspects of FXIII related disorders, including the discovery of the FXIII, associated disorders, molecular basis, diagnosis, and treatment of FXIII deficiency.
    Mesh-Begriff(e) Humans ; Factor XIII Deficiency/diagnosis ; Factor XIII Deficiency/genetics ; Factor XIII Deficiency/therapy ; Factor XIII/genetics ; Factor XIII/metabolism ; Mutation
    Chemische Substanzen Factor XIII (9013-56-3)
    Sprache Englisch
    Erscheinungsdatum 2023-01-27
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 196901-8
    ISSN 1098-9064 ; 0094-6176
    ISSN (online) 1098-9064
    ISSN 0094-6176
    DOI 10.1055/s-0043-1761217
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel: The History of Factor XIII Deficiency

    Dorgalaleh, Akbar

    Seminars in Thrombosis and Hemostasis

    (Celebrating 50 Years of Seminars in Thrombosis and Hemostasis—Part III)

    2023  Band 50, Heft 01, Seite(n) 34–42

    Abstract: Despite the early discovery of factor XIII (FXIII) in 1944, the diagnosis of FXIII deficiency was not made until 1960, after all the other coagulation factor deficiencies, most likely due to the normality of routine coagulation testing in FXIII ... ...

    Serientitel Celebrating 50 Years of Seminars in Thrombosis and Hemostasis—Part III
    Abstract Despite the early discovery of factor XIII (FXIII) in 1944, the diagnosis of FXIII deficiency was not made until 1960, after all the other coagulation factor deficiencies, most likely due to the normality of routine coagulation testing in FXIII deficiency. Although the first case was detected by the clot solubility test and this test has long since been used to detect FXIII deficiency, the test is no longer recommended by experts. Over the past 60 years, knowledge about FXIII deficiency has expanded considerably, between 1992, when the first variant was identified, and 2022, 197 mutations have been reported. Almost all missense mutations have a similar effect on FXIII, leading to instability and faster degradation of mutant FXIII protein. Therapeutic options have evolved from historical fresh frozen plasma (FFP), old plasma, whole blood, and cryoprecipitate, to plasma-derived and recombinant FXIII concentrates, respectively available since 1993 and 2012. These concentrate products were respectively approved by the Food and Drug Administration in 2011 and 2013. This historical review covers various aspects of FXIII related disorders, including the discovery of the FXIII, associated disorders, molecular basis, diagnosis, and treatment of FXIII deficiency.
    Schlagwörter factor XIII deficiency ; factor XIII ; bleeding ; diagnosis ; management
    Sprache Englisch
    Erscheinungsdatum 2023-01-27
    Verlag Thieme Medical Publishers, Inc.
    Erscheinungsort Stuttgart ; New York
    Dokumenttyp Artikel
    ZDB-ID 196901-8
    ISSN 1098-9064 ; 0094-6176
    ISSN (online) 1098-9064
    ISSN 0094-6176
    DOI 10.1055/s-0043-1761217
    Datenquelle Thieme Verlag

    Zusatzmaterialien

    Kategorien

  6. Artikel: Novel Insights into Heterozygous Factor XIII Deficiency

    Dorgalaleh, Akbar

    Seminars in Thrombosis and Hemostasis

    (Editorial Compilation—Part XIV)

    2023  Band 50, Heft 02, Seite(n) 200–212

    Abstract: The prevalence and clinical significance of heterozygous factor XIII (FXIII) deficiency has long been debated, with controversial reports emerging since 1988. In the absence of large epidemiologic studies, but based on a few studies, a prevalence of 1 ... ...

    Serientitel Editorial Compilation—Part XIV
    Abstract The prevalence and clinical significance of heterozygous factor XIII (FXIII) deficiency has long been debated, with controversial reports emerging since 1988. In the absence of large epidemiologic studies, but based on a few studies, a prevalence of 1 per 1,000 to 5,000 is estimated. In southeastern Iran, a hotspot area for the disorder, a study of more than 3,500 individuals found an incidence of 3.5%. Between 1988 and 2023, a total of 308 individuals were found with heterozygous FXIII deficiency, of which molecular, laboratory, and clinical presentations were available for 207 individuals. A total of 49 variants were found in the F13A gene, most of which were missense (61.2%), followed by nonsense (12.2%) and small deletions (12.2%), most occurring in the catalytic domain (52.1%) of the FXIII-A protein and most frequently in exon 4 (17%) of the F13A gene. This pattern is relatively similar to homozygous (severe) FXIII deficiency. In general, heterozygous FXIII deficiency is an asymptomatic condition without spontaneous bleeding tendency, but it can lead to hemorrhagic complications in hemostatic challenges such as trauma, surgery, childbirth, and pregnancy. Postoperative bleeding, postpartum hemorrhage, and miscarriage are the most common clinical manifestations, while impaired wound healing has been rarely reported. Although some of these clinical manifestations can also be observed in the general population, they are more common in heterozygous FXIII deficiency. While studies of heterozygous FXIII deficiency conducted over the past 35 years have shed light on some of the ambiguities of this condition, further studies on a large number of heterozygotes are needed to answer the major questions related to heterozygous FXIII deficiency.
    Schlagwörter factor XIII deficiency ; heterozygous factor XIII deficiency ; miscarriage ; postpartum hemorrhage
    Sprache Englisch
    Erscheinungsdatum 2023-03-20
    Verlag Thieme Medical Publishers, Inc.
    Erscheinungsort Stuttgart ; New York
    Dokumenttyp Artikel
    ZDB-ID 196901-8
    ISSN 1098-9064 ; 0094-6176
    ISSN (online) 1098-9064
    ISSN 0094-6176
    DOI 10.1055/s-0043-1764471
    Datenquelle Thieme Verlag

    Zusatzmaterialien

    Kategorien

  7. Artikel ; Online: Bleeding and Bleeding Risk in COVID-19.

    Dorgalaleh, Akbar

    Seminars in thrombosis and hemostasis

    2020  Band 46, Heft 7, Seite(n) 815–818

    Mesh-Begriff(e) Betacoronavirus ; COVID-19 ; Coronavirus ; Coronavirus Infections ; Humans ; Pandemics ; Pneumonia, Viral ; Prognosis ; SARS-CoV-2
    Schlagwörter covid19
    Sprache Englisch
    Erscheinungsdatum 2020-06-08
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Comment
    ZDB-ID 196901-8
    ISSN 1098-9064 ; 0094-6176
    ISSN (online) 1098-9064
    ISSN 0094-6176
    DOI 10.1055/s-0040-1713434
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  8. Artikel ; Online: Bleeding and Bleeding Risk in COVID-19

    Dorgalaleh, Akbar

    Seminars in Thrombosis and Hemostasis

    2020  Band 46, Heft 07, Seite(n) 815–818

    Schlagwörter Hematology ; Cardiology and Cardiovascular Medicine ; covid19
    Sprache Englisch
    Verlag Georg Thieme Verlag KG
    Erscheinungsland de
    Dokumenttyp Artikel ; Online
    ZDB-ID 196901-8
    ISSN 1098-9064 ; 0094-6176
    ISSN (online) 1098-9064
    ISSN 0094-6176
    DOI 10.1055/s-0040-1713434
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Zusatzmaterialien

    Kategorien

  9. Artikel ; Online: Erratum: Laboratory Diagnosis of Activated Protein C Resistance and Factor V Leiden.

    Bahraini, Mehran / Fazeli, Alieh / Dorgalaleh, Akbar

    Seminars in thrombosis and hemostasis

    2023  

    Sprache Englisch
    Erscheinungsdatum 2023-10-25
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Published Erratum
    ZDB-ID 196901-8
    ISSN 1098-9064 ; 0094-6176
    ISSN (online) 1098-9064
    ISSN 0094-6176
    DOI 10.1055/s-0043-1776324
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang